16-02-10	Ocata Therapeutics : Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries	PR
16-01-22	Ocata Therapeutics : Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics	PR
15-12-28	Ocata Therapeutics : Reports the Publication of Data about the Generation of Corneal Endothelial Cells from Human Pluripotent Stem Cells	BU
15-12-03	Ocata Therapeutics : Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis	BU
15-11-24	Ocata Therapeutics : Harwood Feffer LLP : Announces Investigation of Ocata Therapeutics, Inc.	PR

Manager	Title	Age	Since
John Heffernan PRN	Corporate Officer/Principal	-	2015-02-02

Director	Title	Age	Since
Percival Barretto-Ko BRD	Director/Board Member	53	-
Masaaki Hirano BRD	Director/Board Member	59	-
Toru Yoshimitsu BRD	Director/Board Member	63	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	-0.71%	-0.29%	+56.45%	+107.18%	54.92B
WUXI APPTEC CO., LTD.	-1.22%	+5.01%	+43.38%	+36.69%	44.31B
BIONTECH SE	-1.43%	+3.47%	-15.83%	-20.48%	22.96B
INSMED INCORPORATED	-1.99%	-3.55%	-5.97%	+377.60%	21.12B
WUXI BIOLOGICS (CAYMAN) INC.	-0.13%	+0.81%	+16.50%	-35.89%	16.31B
GENMAB A/S	-2.38%	-3.38%	+5.53%	-41.88%	15.19B
EXELIXIS, INC.	-1.70%	-1.68%	+24.79%	+172.92%	13.32B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.24%	+2.64%	+24.40%	-	12.48B
MADRIGAL PHARMACEUTICALS, INC.	+0.29%	+5.10%	+75.82%	+105.33%	11.52B
Average	-1.40%	+2.14%	+25.01%	+87.69%	23.57B
Weighted average by Cap.	-1.26%	+1.39%	+30.14%	+86.72%